We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Contents
- Definitions
- Rationale for concern about MDR-TB
- Drug resistance increases, treatment success fall
- Managing a severe epidemic of resistance
- The size & distribution of the MDR-TB epidemic
- The global burden of TB 2010
- Distribution of MDR among new TB cases
- Distribution of MDR among previously treated TB
- Estimated MDR-TB incidence rates, 2009
- Highest % of MDR-TB among new cases
- Time trends in TB and MDR-TB
- Countries that reported XDR-TB by end Mar. 2011
- Global strategies, plans and implementation
- MDR & XDR- TB control strategic challenges
- Indicators for PMDT
- Funding increase but lower than planned
- MDR-TB notified, projected & global targets
- MDR-TB treatment enrolment targets 2011
- DST coverage in 2010
- Treatment success
- National level planning and implementation
- Guidance for MDR-TB management programmes
- Why plan MDR-TB treatment programmes?
- Essential principles of care for MDR-TB
- Essential elements in planning TB control
- Specific recommendations for PMDT (1)
- Specific recommendations for PMDT (2)
- Specific recommendations for PMDT (3)
- Specific recommendations for PMDT (4)
- Research gaps
- Obstacles to MDR-TB management
- Only few MDR-TB cases are diagnosed & treated
- Conclusions
- Policy background
- References (1)
- References (2)
- Acknowledgements
Topics Covered
- Definition of common terms
- The rationale for addressing drug resistance
- The size and distribution of the drug resistance epidemic in TB
- Global level plans for addressing it
- National level plans and implementation
- Obstacles and conclusions
- Sources for further study of the policy background
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Nunn, P. (2013, February 28). Drug resistance in tuberculosis and its public health management [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 10, 2024, from https://doi.org/10.69645/BHED7728.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Paul Nunn has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.